Vertex (VERX) shares have skyrocketed 107.3% in the past 12 months, outperforming the Zacks Computer Technology sector, Zacks Internet Software industry and the S&P 500’s return of 38.1%, 40.3% and 26.8%, respectively. This strong performance highlights investor confidence in Vertex's innovative tax compliance solutions, strategic partnerships and expanding client base.Here's why adding Vertex to your portfolio makes sense now.Factors That May Benefit VertexThe increasing adoption of e-invoicing globally an ...

Vertex Pharmaceuticals (VRTX 0.72%) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to doubt the long-term potential of this stock, this setback is an opportunity to buy the dip for those who are willing to hold onto it for at least a few years. Here's why.This growth prospect just took a heavy hitVertex is best known for its therapies for the rare lung disease cystic fibrosis (CF). They provide the v ...

Vertex Pharmaceuticals (VRTX) announced that the FDA has approved its next-in-class vanza triple therapy for treating people with cystic fibrosis (CF) aged six years and above. The drug will be marketed under the brand name Alyftrek.Post the FDA’s approval, the orally administered Alyftrek has been approved for use in CF patients aged six years and older who have at least one F508del mutation or another responsive mutation in the CF transmembrane conductance regulator (CFTR) gene responsive to the drug. The ...

Vertex Pharmaceuticals Inc VRTX last week announced that the Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR) had met its primary endpoint.The company announced that the FDA had approved Alyftrek (or vanzacaftor triple) in cystic fibroris (CF) six years and older, in-line with expectations, according to Goldman Sachs.Analyst Salveen Richter maintained a Buy rating for Vertex Pharmaceuticals and price target of $602.The Vertex Pharmaceuticals Thesis: During the initial launch of Alyft ...

Core Insights - Vertex Pharmaceuticals has experienced a recent decline in stock value, losing nearly 12% in one trading session due to disappointing clinical trial results, but is anticipating significant news in January that could impact revenue substantially [1][4]. Company Overview - Vertex is a leader in cystic fibrosis (CF) treatments, with its CFTR modulators, particularly Trikafta, which was approved in 2019, being effective for approximately 90% of CF patients [2][9]. - The company generated over $9.8 billion in product revenue last year, with a 12% increase to $2.7 billion in the latest quarter, contributing to an 80% stock gain over the past five years [10]. Recent Developments - Vertex has focused on expanding its treatment portfolio beyond CF, achieving a significant milestone with the approval of Casgevy for blood disorders in collaboration with CRISPR Therapeutics [3]. - The company is preparing for two critical regulatory decisions from the FDA regarding the vanza triple and suzetrigine, which could lead to billions in revenue [4][14]. Clinical Trial Insights - A recent phase 2 trial of suzetrigine for sciatica showed a significant drop in pain but also revealed similar performance in the placebo group, raising concerns among investors [12][16]. - Despite the trial results, there is optimism regarding suzetrigine's potential, as it has shown solid results in treating moderate-to-severe acute pain [17]. Market Sentiment - The decline in Vertex's stock may be attributed to profit-taking by investors following substantial gains over the past five years, rather than fundamental weaknesses in the company's prospects [15].

Shares of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) are plummeting today, down 13% at $389.21, after the biotech company's non-opioid painkiller, Suzetrigine, matched the placebo in a phase 2 study. The stock is trading at 52-week lows after the news, earlier falling as low as $377.85, and headed for its worst single-day percentage loss since October 2020. Today's drop has VRTX breaking below support at the $445 level, which has been in place since early October, and dropping into negative territory for 2024 ...

Key TakeawaysVertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which causes leg and back pain.The company said the trial of suzetrigine met its primary endpoint in reducing pain, but a placebo reference arm also showed a "similar within-group reduction from baseline in pain."With Thursday's losses, Vertex shares fell into negative territory for the year. Vertex Pharmaceuticals (VRTX) shares sank Thursday mor ...

Core Insights - Vertex, Inc. has been recognized as a Leader in three IDC MarketScape reports for its tax technology solutions, highlighting its strong position in the market [1] - The recognition underscores Vertex's commitment to empowering businesses with advanced tax technology to navigate complex compliance requirements [1] - Vertex's innovative solutions are designed to support diverse industries and ensure accurate tax determination while integrating with evolving business models [1] Company Overview - Vertex, Inc. is a leading global provider of indirect tax solutions, focusing on delivering trusted tax technology for businesses to transact, comply, and grow confidently [4][5] - The company offers tailored solutions for various lines of indirect tax, including sales and consumer use, value-added tax, and payroll [5] - Vertex employs over 1,500 professionals and operates in North America, South America, and Europe, serving a global clientele [5] Industry Context - The IDC MarketScape vendor assessment model evaluates the competitive fitness of technology and service suppliers, providing a framework for comparing vendors based on qualitative and quantitative criteria [3] - The recognition from IDC emphasizes the importance of intelligent, automated tax management tools for businesses facing global tax complexities [2]

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying strong candidates can be challenging due to associated risks and volatility [1] Group 1: Vertex's Growth Potential - Vertex (VERX) is highlighted as a recommended growth stock with a favorable Growth Score and a top Zacks Rank [2] - The historical EPS growth rate for Vertex is 25.6%, with projected EPS growth of 59% this year, significantly surpassing the industry average of 30.1% [4] - Vertex's year-over-year cash flow growth is 21.3%, compared to an industry average of -14.4%, indicating strong cash flow performance [5] Group 2: Cash Flow and Historical Performance - The annualized cash flow growth rate for Vertex over the past 3-5 years is 42.8%, well above the industry average of 15.2% [6] - Positive trends in earnings estimate revisions have been observed, with the Zacks Consensus Estimate for the current year increasing by 11.1% over the past month [7] Group 3: Overall Assessment - Vertex has achieved a Growth Score of A and a Zacks Rank 2, reflecting positive earnings estimate revisions and strong growth metrics [9] - This combination positions Vertex as a potential outperformer and a solid choice for growth investors [11]